HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Oncolytics Biotech (NASDAQ:ONCY) and maintained a price target of $5. The reaffirmation of the Buy rating and price target suggests a positive outlook on the company's stock.
January 19, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Oncolytics Biotech with a maintained price target of $5, indicating a positive outlook for the stock.
The reiteration of a Buy rating by a reputable analyst typically instills confidence in investors and can lead to a positive short term impact on the stock price. The maintained price target of $5 suggests that the analyst sees potential for significant upside from the current trading level.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100